MedTrace Logo

Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy

NCT01490775 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2018-08-13

No results posted yet for this study

Summary

This study is being conducted in a population of patients with chronic phase Chronic Myeloid Leukemia (CML) to learn more about how patients follow prescribed regimens for taking oral cancer drugs.

Conditions

  • Chronic Phase CML

Interventions

BEHAVIORAL

no access to eMedonline

patients will be followed for 3 months but will not use eMedonline

BEHAVIORAL

eMedonline access

patients will be given access to eMedonline use for 3 months

Sponsors & Collaborators

Principal Investigators

  • Robert Wehbie, MD · Rex Cancer Center - Wakefield

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2015-02-12
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01490775 on ClinicalTrials.gov